Complement activation in diabetic ketoacidosis and its treatment

Rita S. Jerath, C. Lynne Burek, William H. Hoffman, Gregory G. Passmore

Research output: Contribution to journalArticle

Abstract

Recent studies support the presence of an inflammatory response during the treatment of diabetic ketoacidosis (DKA). The objectives of this study were to monitor the complement activation products C3a, C4a, Bb, and C5b-9 prior to, during, and after correction of DKA. All patients had increased levels of C3a at 6-8 h and 24 h (P < 0.05). C4a was increased in only one patient. Bb showed an upward trend at 6-8 h, and was significantly elevated at 24 h (P < 0.05); sC5b-9 was elevated in all patients prior to treatment or in the first 6-8 h of treatment. Results indicate that the alternative pathway may be the primary pathway of activation. These results extend the observation that both DKA and its treatment produce varying degrees of immunologic stress during the time when acute complications are most likely to occur.

Original languageEnglish (US)
Pages (from-to)11-17
Number of pages7
JournalClinical Immunology
Volume116
Issue number1
DOIs
StatePublished - Jul 1 2005

Keywords

  • Bb
  • C3a
  • C5b-9
  • Complement
  • Diabetic ketoacidosis
  • Immunologic stress
  • Systemic inflammatory response

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Complement activation in diabetic ketoacidosis and its treatment'. Together they form a unique fingerprint.

  • Cite this

    Jerath, R. S., Burek, C. L., Hoffman, W. H., & Passmore, G. G. (2005). Complement activation in diabetic ketoacidosis and its treatment. Clinical Immunology, 116(1), 11-17. https://doi.org/10.1016/j.clim.2005.03.004